

**CHAIRS ADDRESS  
MR DAVID AUSTIN  
2021 ANNUAL GENERAL MEETING**

Good morning ladies and gentlemen, on behalf of your Board of Directors, I welcome you to Cann Global's 2021 Annual General Meeting.

Whilst restrictions are beginning to ease, given the nature of the pandemic, as well as public health advice, we are holding today's meeting online, with your Board and management joining from different locations. Every effort has been made to ensure today's meeting is as interactive as possible, including the opportunity for shareholders to ask questions, and the Board and I look forward to taking your questions later in the meeting.

My name is David Austin. Today is my first meeting as Cann Global's Chair. I joined the Cann Global Board in 2019 and moved into the Chairman's role in August last year.

My role today, on behalf of the Board, is to chair this Annual General Meeting, to listen to you, as the owners of our company, share an update on progress, and to do my best to respond to your questions and comments.

Ladies and gentlemen as we have a quorum, I declare the Annual General Meeting of Cann Global Limited open.

Mr Sholom Feldman CEO and Managing Director of Cann Global, and my fellow Director Jonathan Cohen are also present, as is our Company Secretary Alex Neuling.

Stephen Fisher from Nexia the Company's auditors is present and available to answer questions relating to the financial report and audit.

Also present is Rachel Crane from Computershare, the Company's share registry provider, who will carry out a poll once the resolutions have been introduced to the Meeting.

I'd like to begin by thanking Ms Pnina Feldman for her stewardship of the company over the last 13 years and in particular over the period of transitioning from a mining exploration entity to a company focused on leveraging the opportunities within the medical cannabis industry.

In times marked by COVID-19, 2021 has undoubtedly been tough and trying for many Australians. Amidst the uncertainty of the past year, I am proud of the way our management and people continue to deliver on our vision and focus on our customers and shareholders.

## ASX ANNOUNCEMENT



Despite these challenges, Cann Global delivered a strong FY21 result with an improvement in the loss position of 42%, a material increase in cash reserves further strengthening our balance sheet.

I think it's important to put the FY21 result in the context of the initiatives undertaken since 2019 to improve the resilience of the business. Over the past few years, management and our teams have undertaken significant changes resulting in improved commercial terms and lower operating costs. Collectively, these actions set strong foundations for the business to grow and reach profitability.

This is an exciting time for Cann Global as across the globe regulations are changing to support the medicinal cannabis industry and your Company is well positioned to take advantage of these changes.

In Thailand the government have begun issuing licenses to Thai businesses to undertake cultivation, processing and distribution of hemp. Cann Global Thailand as a first mover in the space is already providing services to two of the largest license holders.

A new range of CBD based skincare is being developed, in addition to the hemp-based range, which can be marketed in Europe where cosmetics containing CBD can be sold over the counter under recent regulatory changes.

Cann Global's strategy to continue to innovate and diversify by offering a number of product lines has helped create business resilience during these times of economic uncertainty and also positions the Group to leverage opportunities in a changing industry landscape.

Your board recognises that shareholders are very disappointed about the share price performance. While it is disappointing that Cann Global's share price does not reflect the growth opportunities within the business, I am pleased with the Company's progress towards the launch of new products this financial year.

As your new Chairman, I am delighted to be leading the Company at this pivotal time and I will be working to support our management team who is working hard to drive the Company's vision to fruition and enhance value for our shareholders. I won't reintroduce the Board here however I'd like to make a few remarks about our process of Board renewal and as the board's newly appointed non-executive Chairman tell you a little about my goals for the business.

As your new Independent Chairman, I look forward to enhancing governance and improving transparency, supporting the Management team to achieving the Company's strategic priorities and working with your other directors to deliver shareholder returns.

The board will be implementing a Board Renewal and Succession Policy. The purpose of the policy is to ensure an efficient and effective Board with an appropriate balance of tenure, skill, diversity, and experience and build a renewal

Level 21, 133 Castlereagh Street,  
Sydney NSW 2000 - Australia

Telephone: (02) 8379 1832

[investorrelations@cannglobal.com.au](mailto:investorrelations@cannglobal.com.au)

[www.cannglobal.com.au](http://www.cannglobal.com.au)

## ASX ANNOUNCEMENT



framework that strives to achieve the right mix of skills and experience to create long-term value set within a performance culture.

As a Board, we recognise the importance of balancing the requirements of today's business with maintaining a longer-term outlook – carefully considering risks and opportunities. To do this we are committed to ensuring we have the right people and practices to maintain strong corporate governance.

Cann Global's vision is to become a leader in the production and distribution of high-quality medicinal cannabis, natural health foods and cosmeceutical products. Key to our success is building awareness of the benefits of our products and working with relevant legislative bodies in ensuring appropriate access to these products.

Our competitive strength comes from our team's strong industry expertise, combined with strategic local and global partnerships with experts which support innovation, cultivation, production and distribution activities.

Cann Global has a keen focus on innovation and the pursuit of wholistic wellness putting the consumer first.

The Board and management team continually assess the Company's operating strategy and are confident that diversification supported by synergies and collaboration across the business portfolio will underpin future growth.

The business is focused on four key divisions: health food, hemp cultivation and processing, cosmeceuticals, and medicine. Our vertically integrated approach supports each of our key divisions and this business model is further strengthened by our various global partnerships.

Importantly, we have an ongoing focus on product development, innovation, and research particularly in the field of medicinal cannabis. We are driven to support patients who can benefit from new cannabinoid formulations and are confident that together with evolving legislative frameworks, this can be achieved. The discovery of new medical advancements in treating various autoimmune illnesses remains a significant opportunity for Cann Global.

Cann Global are pleased to have launched the Group's hemp-based skincare range, Fusspot. Marketing to general medical practitioners is also underway for the Canntab products, Instacann. The plant funding model operated by Cann Global Thailand also began receiving revenue this financial year. Mr Feldman will update you further on this progress in his address.

Level 21, 133 Castlereagh Street,  
Sydney NSW 2000 - Australia

Telephone: (02) 8379 1832

[investorrelations@cannglobal.com.au](mailto:investorrelations@cannglobal.com.au)

[www.cannglobal.com.au](http://www.cannglobal.com.au)

## ASX ANNOUNCEMENT



On behalf of the Board, I would like to thank our management team and our employees for their hard work and dedication during the year, our customers without whom there would be no business, and you, our shareholders for your continued support for our company. I want to personally thank each shareholder that participated in the two equity raisings during the 2021 financial year and more recently in December, allowing the business to clear its liabilities and providing the business with a strong balance sheet to pursue its growth strategies.

I will now hand over to your CEO Sholom Feldman to give you an update on the business' operations.

### ABOUT CANNGLOBAL

Cann Global Limited (ASX:CGB) is a driving force in the hemp and medical Cannabis industries. Our strength comes from our team's core competencies and expertise, and our solid and strategic partnerships with experts in Australia, USA, Israel, Asia, Africa and Canada. We are working under the relevant legislation to ensure that the future in Medical Cannabis and Natural Foods will allow medical practitioners, patients, and consumers to gain access to the right information, as well as the safest, most effective and sustainable products.

### AUTHORITY AND CONTACT DETAILS

This announcement has been authorised for release by Sholom Feldman, Managing Director. For further information please contact Investor Relations on +61 (0)2 8379 1832, or via email at [investorrelations@cannglobal.com.au](mailto:investorrelations@cannglobal.com.au)

Level 21, 133 Castlereagh Street,  
Sydney NSW 2000 - Australia

Telephone: (02) 8379 1832

[investorrelations@cannglobal.com.au](mailto:investorrelations@cannglobal.com.au)

[www.cannglobal.com.au](http://www.cannglobal.com.au)